Barchart.com
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Brandes International ETF (BINV)

Brandes International ETF (BINV)
N/A x N/A 47.29 x 1
Post-market by (Cboe BZX)
31.56 +0.98 (+3.20%) 04/11/25 [NYSE Arca]
N/A x N/A 47.29 x 1
Post-market 31.56 unch (unch) 20:00 ET
News & Headlines for Fri, Apr 11th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022 Business Wire - Mon Nov 14, 2022

Regulatory News:

BINV : 31.56 (+3.20%)
CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINA PR Newswire - Wed Sep 7, 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 1.9500 (+2.09%)
BINV : 31.56 (+3.20%)
Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA® Business Wire - Tue Jun 28, 2022

Regulatory News:

BINV : 31.56 (+3.20%)
Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA® Business Wire - Tue Jun 28, 2022

Regulatory News:

BINV : 31.56 (+3.20%)
Transgene and BioInvent Announce Positive Progress for BT-001 Business Wire - Mon Jun 27, 2022

Regulatory News:

BINV : 31.56 (+3.20%)
Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies Business Wire - Wed Jun 15, 2022

Exelixis, Inc. (Nasdaq: EXEL) and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV) today announced that the companies have entered into an option and license agreement focused on...

EXEL : 35.31 (+2.47%)
BINV : 31.56 (+3.20%)
Transgene and BioInvent Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD1/ Anti-CTLA-4 Immune Checkpoint Blockade Business Wire - Thu Jan 20, 2022

Regulatory News:

BINV : 31.56 (+3.20%)
BioInvent Moves to NASDAQ Stockholm’s Mid Cap Segment ACCESS Newswire - Mon Dec 20, 2021

LUND, SWEDEN / ACCESSWIRE / December 20, 2021 / BioInvent International (STO:BINV) Lund, Sweden - December 20, 2021 - BioInvent International AB ("BioInvent") (NASDAQ Stockholm: BINV), a biotech company...

BINV : 31.56 (+3.20%)
BioInvent announces positive early data from ongoing solid cancer trial of BI-1206 in combination with pembrolizumab ACCESS Newswire - Fri Dec 17, 2021

LUND, SE / ACCESSWIRE / December 17, 2021 / BioInvent International (STO:BINV) - Partial response in metastatic uveal melanoma, a difficult-to-treat indication - Markedly improvement of stage IV sarcoma...

BINV : 31.56 (+3.20%)
MRK : 79.18 (+2.10%)
BioInvent’s Latest NHL Data at ASH Show Increased and Sustained Responses to BI-1206 in Relapsed Patients ACCESS Newswire - Sat Dec 11, 2021

- Objective response rate (ORR) 67% and disease control rate (DCR) 78% in Follicular lymphoma - Complete responses lasting beyond 18, 24 and 36 months LUND, SWEDEN / ACCESSWIRE / December 11, 2021 / BioInvent...

BINV : 31.56 (+3.20%)

Barchart Exclusives

Analysts Still Have a Near-Perfect Rating on This ‘Strong Buy’ Quantum Computing Stock Barchart - Sat Apr 12, 12:00PM CDT
Down 25% from all-time highs, Amazon is a quantum computing stock that trades at a discount to price targets in April 2025. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
UTC
Reserve Your Spot